Poxel SA

Poxel SA is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for serious chronic diseases with metabolic pathophysiology. Headquartered in Lyon, France, the company focuses its research and development efforts primarily on non-alcoholic steatohepatitis (NASH) and various rare metabolic disorders.

The company's pipeline includes several drug candidates. TWYMEEG® (Imeglimin), a first-in-class product targeting mitochondrial dysfunction, received approval in 2021 and is currently marketed for the treatment of type 2 diabetes in Japan by its partner, Sumitomo Pharma, generating royalties and sales-based payments for Poxel. PXL065, a deuterium-stabilized R-pioglitazone, is being developed for NASH and has successfully met its primary endpoint in a streamlined Phase 2 trial.

In recent developments, Poxel announced the sale of its drug candidate PXL770, a direct AMPK activator previously focused on rare diseases like adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD), to Scynexis for up to $196 million in March 2026. This strategic move allows Poxel to concentrate its resources on TWYMEEG® and PXL065. Nicolas Trouche serves as the CEO, leading the company in its pursuit of new partnerships and value creation within the biopharmaceutical landscape.

Latest updates

Poxel Delays Financial Reporting Amid Complex Funding and Asset Sale

Event summary

  • Poxel has postponed the release of its 2025 annual financial statements and report, initially slated for May 2026.
  • The delay stems from the accounting complexities arising from a €5 million equity financing facility with IRIS, a €7.5 million PDR subscription agreement with IPF Invest Co 2 and IPF Management, and the sale of PXL770 to Scynexis.
  • Planned capital increases, including those with IPF Invest Co 2, are also postponed to coincide with the transfer to Euronext Growth and ensure shareholders have complete information.
  • The company now expects to approve the financial statements on June 5, 2026, publish the report on June 15, 2026, and hold the AGM on July 23, 2026.

The big picture

Poxel's situation reflects a broader trend of smaller biopharma companies facing liquidity challenges and relying on complex financing structures to stay afloat. The company's reliance on asset sales to fund operations and the delayed financial reporting raise concerns about its long-term viability. The transfer to Euronext Growth, while potentially offering increased visibility, also signals a desire to access a different investor base and potentially lower listing requirements.

What we're watching

Governance Dynamics
The postponement of capital increases and the transfer to Euronext Growth suggest ongoing governance adjustments and a desire to present a more stable financial picture to investors.
Financial Health
The need for complex accounting treatment related to recent transactions indicates potential fragility in Poxel’s financial position and warrants close scrutiny of the delayed financial statements.
Asset Monetization
The sale of PXL770 and subsequent increase in the IPF subscription agreement highlight Poxel’s reliance on asset sales to bolster its finances, raising questions about the sustainability of this strategy.
CID: 3641